Burning Rock and Boehringer Ingelheim Inked a Master Service Agreement in Oncology Companion Diagnostics

Author: Benzinga Newsdesk | October 30, 2023 03:25am

Burning Rock Biotech Limited (NASDAQ:BNR, the ", Company", or ", Burning Rock", ))))) is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics. This agreement aims to provide Chinese patients with safer, more efficient, and precise treatment options and diagnostic methods, thereby promoting innovation and development in cancer treatment. This partnership will primarily focus on advancing the clinical trials related to Boehringer Ingelheim's MDM2-p53 antagonist, brigimadlin (BI 907828), and the development of companion diagnostic products in China.

Posted In: BNR